Unconventional nuclides for radiopharmaceuticals.
Rapid and widespread growth in the use of nuclear medicine for both diagnosis and therapy of disease has been the driving force behind burgeoning research interests in the design of novel radiopharmaceuticals. Until recently, the majority of clinical and basic science research has focused on the development of 11C-, 13N-, 15O-, and 18F-radiopharmaceuticals for use with positron emission tomography (PET) and 99mTc-labeled agents for use with single-photon emission computed tomography (SPECT). With the increased availability of small, low-energy cyclotrons and improvements in both cyclotron targetry and purification chemistries, the use of "nonstandard" radionuclides is becoming more prevalent. This brief review describes the physical characteristics of 60 radionuclides, including beta+, beta-, gamma-ray, and alpha-particle emitters, which have the potential for use in the design and synthesis of the next generation of diagnostic and/or radiotherapeutic drugs. As the decay processes of many of the radionuclides described herein involve emission of high-energy gamma-rays, relevant shielding and radiation safety issues are also considered. In particular, the properties and safety considerations associated with the increasingly prevalent PET nuclides 64Cu, 68Ga, 86Y, 89Zr, and 124I are discussed.
Radiochemistry Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Jason P
JP
Holland
Matthew J
MJ
Williamson
Jason S
JS
Lewis
D006801:Humans; D009683:Nuclear Medicine / Q000379:methods; D049268:Positron-Emission Tomography; D011839:Radiation, Ionizing; D011868:Radioisotopes / Q000737:chemistry / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000737:chemistry / Q000627:therapeutic use*; D011878:Radiotherapy / Q000379:methods; D015899:Tomography, Emission-Computed, Single-Photon
D011868:Radioisotopes; D019275:Radiopharmaceuticals